Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.30 USD
-0.47 (-2.80%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $16.24 -0.06 (-0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGEM 16.30 -0.47(-2.80%)
Will CGEM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
Other News for CGEM
Morgan Stanley Remains a Buy on Cullinan Management (CGEM)
Wedbush Remains a Buy on Cullinan Management (CGEM)
Cullinan Management: A Buy Rating on Strong Financials and Promising Clinical Trials
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024